Clinical Trial Update: Veliparib, Cyclophosphamide, and Doxorubicin Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Non-Hodgkin Lymphoma [Phase 1]

View source ↗

Summary

Phase 1 clinical trial evaluating veliparib in combination with cyclophosphamide and doxorubicin hydrochloride for patients with metastatic or unresectable soli…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-hodgkin Lymphoma
• Solid Tumors

Drugs mentioned

• CYCLOPHOSPHAMIDE (Cyclophosphamide)
• DOXORUBICIN HYDROCHLORIDE (Doxorubicin hydrochloride)
• Veliparib (veliparib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Ann Arbor Stage III Non-Hodgkin Lymphoma, Ann Arbor Stage IV Non-Hodgkin Lymphoma | Phase 1 | Status: ACTIVE_NOT_RECRUITING